FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211282201> ?p ?o ?g. }

• W3211282201 endingPage "S58" @default.
• W3211282201 startingPage "S58" @default.
• W3211282201 abstract "Purpose/Objective(s)This study characterizes the efficacy and safety of stereotactic body radiation therapy (SBRT) with immunotherapy in the treatment of abdominal and pelvic lymph node metastases, based on a pooled analysis of three prospective phase I trials. While SBRT is frequently utilized for metastases, its role in the treatment of abdominal and pelvic lymphadenopathy remains unclear. We hypothesize that local control will remain excellent for nodal SBRT, even with prioritization of organ-at-risk (OAR) constraints resulting in undercoverage of target metastases and with omission of elective treatment of regional nodal basins.Materials/MethodsPatients with widely metastatic solid malignancies were enrolled on three Phase I trials between 2016 and 2020 (total 213 patients). Patients were treated with multisite SBRT (up to 4 sites). Metastases > 65cc were partially treated. Immunotherapy was administered either concurrently or sequentially. Immunotherapy regimens included pembrolizumab, ipilimumab with nivolumab, urelumab with nivolumab, or cabiralizumab with nivolumab. The study cohort included patients who underwent SBRT to at least one lymph node in the abdomen or pelvis, including the inguinal regions. Local control (LC) of irradiated metastases and regional control (RC) of the corresponding nodal basin were determined per RECIST 1.1 guidelines. Overall survival (OS) was calculated using the Kaplan-Meier method. For each irradiated lesion, the mean dose, V95%, and V100% to the ITV and PTV were recorded.ResultsA total of 39 patients (mean age 59.2 years) underwent SBRT to 56 abdominal or pelvic lymph node metastases with median follow-up of 16.2 months. The median prescription dose was 45 Gy in 3 fractions. Median lesion volume was 17.0cc. Lymph node sites included 24 para-aortic/retroperitoneal (43%), 9 pelvic (16%), 11 inguinal (20%), 10 gastrohepatic/porta hepatis (18%), and 2 other (4%). Across all patients, the 1-year LC was 90.4%. Even without elective treatment of the corresponding nodal basins, 1-year RC was 81.9% (with only one isolated regional failure without concomitant distant progression). Median OS was 25 months, while 1-year and 2-year OS were 69.9% and 53.2%, respectively. ITV mean dose, V95%, and V100% were 47.3 Gy, 95.3%, and 89.5%, respectively (reported as medians across all 56 metastases). PTV mean dose, V95%, and V100% were 45.5 Gy, 84.2%, and 75.0%, respectively. The overall incidence of grade 3+ toxicity was 10.3%. The incidence of grade 3 colitis was 2.6% and grade 3 hepatitis was 2.6%, with no grade 4-5 colitis/hepatitis events.ConclusionIn this pooled analysis of three prospective trials, SBRT to abdominal or pelvic lymph node metastases with immunotherapy is associated with acceptable toxicity and high rates of LC, even with target undercoverage to meet OAR constraints. This suggests a potential for this approach in clinical practice and study in future trials. This study characterizes the efficacy and safety of stereotactic body radiation therapy (SBRT) with immunotherapy in the treatment of abdominal and pelvic lymph node metastases, based on a pooled analysis of three prospective phase I trials. While SBRT is frequently utilized for metastases, its role in the treatment of abdominal and pelvic lymphadenopathy remains unclear. We hypothesize that local control will remain excellent for nodal SBRT, even with prioritization of organ-at-risk (OAR) constraints resulting in undercoverage of target metastases and with omission of elective treatment of regional nodal basins. Patients with widely metastatic solid malignancies were enrolled on three Phase I trials between 2016 and 2020 (total 213 patients). Patients were treated with multisite SBRT (up to 4 sites). Metastases > 65cc were partially treated. Immunotherapy was administered either concurrently or sequentially. Immunotherapy regimens included pembrolizumab, ipilimumab with nivolumab, urelumab with nivolumab, or cabiralizumab with nivolumab. The study cohort included patients who underwent SBRT to at least one lymph node in the abdomen or pelvis, including the inguinal regions. Local control (LC) of irradiated metastases and regional control (RC) of the corresponding nodal basin were determined per RECIST 1.1 guidelines. Overall survival (OS) was calculated using the Kaplan-Meier method. For each irradiated lesion, the mean dose, V95%, and V100% to the ITV and PTV were recorded. A total of 39 patients (mean age 59.2 years) underwent SBRT to 56 abdominal or pelvic lymph node metastases with median follow-up of 16.2 months. The median prescription dose was 45 Gy in 3 fractions. Median lesion volume was 17.0cc. Lymph node sites included 24 para-aortic/retroperitoneal (43%), 9 pelvic (16%), 11 inguinal (20%), 10 gastrohepatic/porta hepatis (18%), and 2 other (4%). Across all patients, the 1-year LC was 90.4%. Even without elective treatment of the corresponding nodal basins, 1-year RC was 81.9% (with only one isolated regional failure without concomitant distant progression). Median OS was 25 months, while 1-year and 2-year OS were 69.9% and 53.2%, respectively. ITV mean dose, V95%, and V100% were 47.3 Gy, 95.3%, and 89.5%, respectively (reported as medians across all 56 metastases). PTV mean dose, V95%, and V100% were 45.5 Gy, 84.2%, and 75.0%, respectively. The overall incidence of grade 3+ toxicity was 10.3%. The incidence of grade 3 colitis was 2.6% and grade 3 hepatitis was 2.6%, with no grade 4-5 colitis/hepatitis events. In this pooled analysis of three prospective trials, SBRT to abdominal or pelvic lymph node metastases with immunotherapy is associated with acceptable toxicity and high rates of LC, even with target undercoverage to meet OAR constraints. This suggests a potential for this approach in clinical practice and study in future trials." @default.
• W3211282201 created "2021-11-08" @default.
• W3211282201 creator A5003800857 @default.
• W3211282201 creator A5024933832 @default.
• W3211282201 creator A5030967817 @default.
• W3211282201 creator A5037640782 @default.
• W3211282201 creator A5042973687 @default.
• W3211282201 creator A5045294159 @default.
• W3211282201 creator A5055476105 @default.
• W3211282201 creator A5063337705 @default.
• W3211282201 creator A5073604255 @default.
• W3211282201 creator A5078430875 @default.
• W3211282201 date "2021-11-01" @default.
• W3211282201 modified "2023-10-02" @default.
• W3211282201 title "Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases" @default.
• W3211282201 doi "https://doi.org/10.1016/j.ijrobp.2021.07.149" @default.
• W3211282201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700587" @default.
• W3211282201 hasPublicationYear "2021" @default.
• W3211282201 type Work @default.
• W3211282201 sameAs 3211282201 @default.
• W3211282201 citedByCount "0" @default.
• W3211282201 crossrefType "journal-article" @default.
• W3211282201 hasAuthorship W3211282201A5003800857 @default.
• W3211282201 hasAuthorship W3211282201A5024933832 @default.
• W3211282201 hasAuthorship W3211282201A5030967817 @default.
• W3211282201 hasAuthorship W3211282201A5037640782 @default.
• W3211282201 hasAuthorship W3211282201A5042973687 @default.
• W3211282201 hasAuthorship W3211282201A5045294159 @default.
• W3211282201 hasAuthorship W3211282201A5055476105 @default.
• W3211282201 hasAuthorship W3211282201A5063337705 @default.
• W3211282201 hasAuthorship W3211282201A5073604255 @default.
• W3211282201 hasAuthorship W3211282201A5078430875 @default.
• W3211282201 hasBestOaLocation W32112822011 @default.
• W3211282201 hasConcept C121608353 @default.
• W3211282201 hasConcept C126322002 @default.
• W3211282201 hasConcept C126838900 @default.
• W3211282201 hasConcept C141071460 @default.
• W3211282201 hasConcept C2777701055 @default.
• W3211282201 hasConcept C2779983558 @default.
• W3211282201 hasConcept C2780030458 @default.
• W3211282201 hasConcept C2780849966 @default.
• W3211282201 hasConcept C2781433595 @default.
• W3211282201 hasConcept C509974204 @default.
• W3211282201 hasConcept C71924100 @default.
• W3211282201 hasConceptScore W3211282201C121608353 @default.
• W3211282201 hasConceptScore W3211282201C126322002 @default.
• W3211282201 hasConceptScore W3211282201C126838900 @default.
• W3211282201 hasConceptScore W3211282201C141071460 @default.
• W3211282201 hasConceptScore W3211282201C2777701055 @default.
• W3211282201 hasConceptScore W3211282201C2779983558 @default.
• W3211282201 hasConceptScore W3211282201C2780030458 @default.
• W3211282201 hasConceptScore W3211282201C2780849966 @default.
• W3211282201 hasConceptScore W3211282201C2781433595 @default.
• W3211282201 hasConceptScore W3211282201C509974204 @default.
• W3211282201 hasConceptScore W3211282201C71924100 @default.
• W3211282201 hasIssue "3" @default.
• W3211282201 hasLocation W32112822011 @default.
• W3211282201 hasLocation W32112822012 @default.
• W3211282201 hasOpenAccess W3211282201 @default.
• W3211282201 hasPrimaryLocation W32112822011 @default.
• W3211282201 hasRelatedWork W2285109017 @default.
• W3211282201 hasRelatedWork W2557486166 @default.
• W3211282201 hasRelatedWork W2794625598 @default.
• W3211282201 hasRelatedWork W2797778196 @default.
• W3211282201 hasRelatedWork W2897550585 @default.
• W3211282201 hasRelatedWork W2898645881 @default.
• W3211282201 hasRelatedWork W2968308034 @default.
• W3211282201 hasRelatedWork W2969738919 @default.
• W3211282201 hasRelatedWork W3001671128 @default.
• W3211282201 hasRelatedWork W4319163597 @default.
• W3211282201 hasVolume "111" @default.
• W3211282201 isParatext "false" @default.
• W3211282201 isRetracted "false" @default.
• W3211282201 magId "3211282201" @default.
• W3211282201 workType "article" @default.